Minh Vu
Optometrist · New York, NYNPI 1013449305
Payments from drug & device makers
Across 67 payments — averaging $136.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$6K
- AbbVie$758
- Coopervision Inc.$747
- Bausch & Lomb Americas Inc.$723
- Kala Pharmaceuticals, Inc.$227
- Mallinckrodt Hospital Products Inc.$181
- plus $627 from 14 others
What the payments were for
- Food & beverage$9,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 4 | $5,915 |
| AbbVie(2 entities) | 12 | $758 |
| Coopervision Inc. | 12 | $747 |
| Bausch & Lomb Americas Inc. | 12 | $723 |
| Kala Pharmaceuticals, Inc. | 7 | $227 |
| Mallinckrodt Hospital Products Inc. | 2 | $181 |
| Eyevance Pharmaceuticals LLC | 2 | $150 |
| Johnson & Johnson Vision Care, Inc. | 2 | $133 |
| Harrow Eye, LLC | 2 | $59 |
| Tarsus Pharmaceuticals, Inc. | 2 | $51 |
| Sight Sciences, Inc. | 1 | $36 |
| Rxsight Inc | 1 | $28 |
| Dompe US, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $24 |
| Alcon | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Amgen | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$3,915
- M22$2,000
- LUMIGAN$381
- MiSight Contact Lens$224
- INFUSE$150
- ACTHAR$147
- enVista MX60 IOL$142
- RESTASIS$125
- Paragon CRT$120
- Acuvue$108
- INVELTYS$107
How this compares
$9,178 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 15 | $10,129 |
| Latanoprost | 11 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $758 | $10,12915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in New York
- George ZikosNew York$1M
- Irene FrantzisNew York$663K
- Daphne AmbroseNew York$509K
- Susan ResnickNew York$463K
- Denise WhittamNew York$343K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Danielle IaconoNew York$206K
- Jason ComptonNew York$197K
- John RobilottoNew York$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.